FIGURES




FIG. 1



SCREENING/RANDOMIZATION
TREATMENT PERIOD 1
WASHOUT
TREATMENT PERIOD 2
FOLLOW-UP
BIIB074
400 mg BID REPEAT DOSE
(MALE SUBJECTS)
300 mg BID REPEAT DOSE
(FEMALE SUBJECTS)
PLACEBO
BIIB074 400 mg
SINGLE DOSE*
(FEMALE SUBJECTS)
PROTOCOL:
TIMELINE:
30 DAYS
36 DAYS
7 DAYS
36 DAYS
7-14 DAYS
PERIOD 1
BASELINE VISIT
PERIOD 2
BASELINE VISIT
*Administered 7 days prior to treatment period 1 baseline visit

FIG. 2



A
MEAN CHANGE OVER 24 h IN SYSTOLIC BLOOD PRESSURE FROM BASELINE TO DAY 36 (OUTPATIENT)
MEAN (SD) IN cfb SBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
PLACEBO
GSK1014802 300-400 mg RD
0
6
12
18
24
TIME [h] RELATIVE TO a.m. DOSING
B
MEAN CHANGE OVER 24 h IN DIASTOLIC BLOOD PRESSURE FROM BASELINE TO DAY 36 (OUTPATIENT)
MEAN (SD) IN cfb DBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
PLACEBO
GSK1014802 300-400 mg RD
0
6
12
18
24
TIME [h] RELATIVE TO a.m. DOSING

FIG. 3



A
PROPORTION OF CHANGE FROM BASELINE OBSERVATIONS OF INTEREST IN SYSTOLIC BLOOD PRESSURE OVER 24 h ON DAY 36 (OUTPATIENT)
PLACEBO
GSK1014802 300-400 mg BD
PERCENTAGE
0
10
20
30
40
50
>30
>30 TO <=20
>20 TO <=10
>-10 TO <=0
>0 TO <=10
>10 TO <=20
>20 TO <=30
>30
CHANGE FROM BASELINE IN SBP (mmHg)
B
PROPORTION OF CHANGE FROM BASELINE OBSERVATIONS OF INTEREST IN SYSTOLIC BLOOD PRESSURE OVER 24 h ON DAY 36 (OUTPATIENT)
PLACEBO
GSK1014802 300-400 mg BD
PERCENTAGE
0
10
20
30
40
>20
>=20 TO <=15
>15 TO <=10
>10 TO <=5
>5 TO <=0
>0 TO <=5
>5 TO <=10
>10 TO <=15
>15 TO <=20
>20
CHANGE FROM BASELINE IN SBP (mmHg)

FIG. 4



A
MEAN CHANGE OVER 24 h IN SYSTOLIC BLOOD PRESSURE FROM BASELINE TO DAY 35 (INPATIENT)
MEAN (SD) IN chb SBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
0
6
12
TIME [h] RELATIVE TO a.m. DOSING
B
MEAN CHANGE OVER 24 h IN DIASTOLIC BLOOD PRESSURE FROM BASELINE TO DAY 35 (INPATIENT)
MEAN (SD) IN chb DBP (mmHg)
10
8
6
4
2
0
-2
-4
-6
-8
-10
0
6
12
TIME [h] RELATIVE TO a.m. DOSING

FIG. 5



Linear Scale
Semi-Logarithmic Scale
Mean (±SD) Plasma Concentration (ng/mL)
Mean Plasma Concentration (ng/mL)
Hours Post Dose
Treatment
BIIB074 alone (N = 30)
BIIB074 with valproic acid (N = 28)

FIG. 6



Linear Scale
Semi-Logarithmic Scale
Mean (±SD) Plasma Concentration (ng/mL)
Mean Plasma Concentration (ng/mL)
Hours Post Dose
Treatment
BIIB074 alone (N = 30)
BIIB074 with valproic acid (N = 28)

FIG. 7



Linear Scale
Semi-Logarithmic Scale
Mean (±SD) Plasma Concentration (ng/mL)
Hours Post Dose
Treatment
BIIB074 alone (N = 30)
BIIB074 with valproic acid (N = 28)
Analyte: CNY2283325 (M14) (ng/mL)
NOTE: Lower Limit of Quantification=10.0 (ng/mL). BLQ is treated as missing. Non-determinable is set to missing.

FIG. 8



Linear Scale
Semi-Logarithmic Scale
Mean (±SD) Plasma Concentration (ng/mL)
Mean Plasma Concentration (ng/mL)
Hours Post Dose
0 2 4 6 8 12 16 24 48 72 96 120 144 168
Treatment
BIIB074 alone (N = 30)
BIIB074 with valproic acid (N = 28)

FIG. 9